Edition:
India

Transgene Presents Data Supporting Myvac Platform


Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - TRANSGENE SA ::TRANSGENE PRESENTS FIRST PRECLINICAL AND TRANSLATIONAL DATA SUPPORTING ITS NOVEL MYVAC™ PLATFORM.SET UP PROCESS AIMED AT DEVELOPING A MODIFIED VACCINIA VIRUS ANKARA (MVA)-BASED, INDIVIDUALIZED IMMUNOTHERAPY PRODUCT THAT RECOGNIZES AND DESTROYS TUMORS.IMMUNOGENICITY OF INDIVIDUALIZED VACCINE HAS BEEN DEMONSTRATED IN A HUMANIZED MICE MODEL..IMMUNE RESPONSE OBSERVED IN MICE MODEL PARTLY OVERLAPS WITH ONE OBSERVED IN HUMANS.